New Treatments Redefine Asthma Care, Improve Patient Health
Physician-authored paper highlights how innovative treatments can improve patient outcomes and why access is critical
WASHINGTON, May 8, 2024 /PRNewswire/ -- For decades, the inhaler has been the go-to treatment for asthma, but innovative options like biologics are changing how providers tailor care.
"Breath of Fresh Care," a physician-authored paper from the Alliance for Patient Access, highlights recent innovations in the field of asthma care. J. Allen Meadows, MD, discusses how innovative treatments are giving patients more targeted options that meet each patient's needs.
Making Asthma Care Accessible & Affordable
While these treatments can be game changers for patients, access is critical. Barriers can get in the way, hindering patient care and harming the patient-provider relationship.
Utilization management tactics like prior authorization and step therapy can prevent patients from accessing their treatment in a timely manner.
Pharmacy benefit managers may create formularies that exclude these treatments, forcing patients to use other, less effective medications.
Copay diversion programs like alternative funding programs can complicate how patients access their medication and leave patients with significant out-of-pocket costs.
Definitions of value from organizations like ICER may impact whether a medication receives coverage without weighing patient values and perspectives.
Policies that reduce these barriers can make a big difference. With the right care, asthma patients will be able to breathe easier.
STATEMENT FROM J. ALLEN MEADOWS, MD: "The right treatment can go a long way ? it can reduce kids' absences at school, it can improve adults' productivity, it can reduce emergency room visits. It's amazing how far asthma treatments have come during my lifetime."
About the Alliance for Patient Access
The Alliance for Patient Access is a network of policy-minded health care providers who advocate for patient-centered care.
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company"). This action, captioned Hope v. agilon health, inc., et...
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market. The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...